Exenatide, the first commercially available GLP-1 analogue, has been mentioned in the latest NICE guidelines for those with a BMI >35, an HbA1c >7.5%, on maximum oral metformin and sulphonylurea, who would otherwise be starting a high-cost medication.
NICE also mention criteria for success: a weight loss >5% at one year and improvement in HbA1c >1%
The audit is limited in scope as not many patients have been on the medication 6 months, let alone one year.
The interesting issues are that we are using it off-licence (i.e in those already on insulin) and that doesn't seem to influence outcome.
Here is the audit. Other peoples thoughts, experiences and comments would be useful... just use the comments link at the bottom of this post.
Exenatide Presentation
View more presentations from PeninsulaEndocrine.
No comments:
Post a Comment